MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) – HC Wainwright lifted their Q3 2026 earnings estimates for shares of MiNK Therapeutics in a research note issued on Friday, August 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.35) per share for the quarter, up from their prior forecast of ($0.63). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.93) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($2.39) EPS, FY2029 earnings at ($1.67) EPS and FY2030 earnings at $0.06 EPS.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02).
Get Our Latest Analysis on INKT
MiNK Therapeutics Trading Down 0.4%
Shares of NASDAQ:INKT opened at $11.22 on Tuesday. MiNK Therapeutics has a 12 month low of $8.48 and a 12 month high of $16.98. The company has a 50-day moving average price of $11.33 and a 200-day moving average price of $11.21. The company has a market cap of $55.88 million, a price-to-earnings ratio of -4.67 and a beta of 0.48.
Hedge Funds Weigh In On MiNK Therapeutics
A hedge fund recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned 0.55% of MiNK Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 2.87% of the company’s stock.
About MiNK Therapeutics
MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.
MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.
Further Reading
- Five stocks we like better than MiNK Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
